BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women

PHASE2CompletedINTERVENTIONAL
Enrollment

3,101

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
HIV Infections
Interventions
DRUG

BufferGel

Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of BufferGel intravaginally up to 60 minutes before each vaginal intercourse while in the study.

DRUG

PRO 2000/5 Gel

Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.

DRUG

Placebo gel

Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.

Trial Locations (8)

263

Seke South CRS, Chitungwiza

Spilhaus CRS, Harare

Unknown

3535 Market Street CRS, Philadelphia

University of North Carolina Lilongwe CRS, Lilongwe

College of Med. JHU CRS, Blantyre

Chatsworth CRS, Chatsworth

Med. Research Council-Hlabisa, Durban

Kamwala Clinic CRS, Lusaka

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

National Institute of Mental Health (NIMH)

NIH

collaborator

HIV Prevention Trials Network

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00074425 - BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women | Biotech Hunter | Biotech Hunter